These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

409 related articles for article (PubMed ID: 33765180)

  • 21. Antidiabetic agents and risk of atrial fibrillation/flutter: A comparative critical analysis with a focus on differences between SGLT2 inhibitors and GLP-1 receptor agonists.
    Scheen AJ
    Diabetes Metab; 2022 Nov; 48(6):101390. PubMed ID: 36170946
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Diabetes Mellitus, Glycemic Traits, and Cerebrovascular Disease: A Mendelian Randomization Study.
    Georgakis MK; Harshfield EL; Malik R; Franceschini N; Langenberg C; Wareham NJ; Markus HS; Dichgans M
    Neurology; 2021 Mar; 96(13):e1732-e1742. PubMed ID: 33495378
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Impact of Current and Emerging Glucose-Lowering Drugs on Body Weight in Type 2 Diabetes.
    Lau DC; Teoh H
    Can J Diabetes; 2015 Dec; 39 Suppl 5():S148-54. PubMed ID: 26654858
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Genetically proxied antidiabetic drugs targets and stroke risk.
    Zhu Y; Li M; Wang H; Yang F; Pang X; Du R; Zhang J; Huang X
    J Transl Med; 2023 Sep; 21(1):681. PubMed ID: 37777789
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of glucose-lowering agents on surrogate endpoints and hard clinical renal outcomes in patients with type 2 diabetes.
    Scheen AJ
    Diabetes Metab; 2019 Apr; 45(2):110-121. PubMed ID: 30477733
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of the effect of glucose-lowering agents on the risk of atrial fibrillation: A network meta-analysis.
    Shi W; Zhang W; Zhang D; Ren G; Wang P; Gao L; Chen H; Ding C
    Heart Rhythm; 2021 Jul; 18(7):1090-1096. PubMed ID: 33684547
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Glycemic control of type 2 diabetes mellitus across stages of renal impairment: information for primary care providers.
    Tong L; Adler S
    Postgrad Med; 2018 May; 130(4):381-393. PubMed ID: 29667921
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of glucose-lowering therapies on heart failure.
    Nassif M; Kosiborod M
    Nat Rev Cardiol; 2018 May; 15(5):282-291. PubMed ID: 29368701
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Glucose-lowering action through targeting islet dysfunction in type 2 diabetes: Focus on dipeptidyl peptidase-4 inhibition.
    Ahrén B
    J Diabetes Investig; 2021 Jul; 12(7):1128-1135. PubMed ID: 33949781
    [TBL] [Abstract][Full Text] [Related]  

  • 30. No evidence that genetically reduced 25-hydroxyvitamin D is associated with increased risk of ischaemic heart disease or myocardial infarction: a Mendelian randomization study.
    Brøndum-Jacobsen P; Benn M; Afzal S; Nordestgaard BG
    Int J Epidemiol; 2015 Apr; 44(2):651-61. PubMed ID: 25981321
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Association Between Sodium-Glucose Cotransporter 2 Inhibitors and Lower Extremity Amputation Among Patients With Type 2 Diabetes.
    Chang HY; Singh S; Mansour O; Baksh S; Alexander GC
    JAMA Intern Med; 2018 Sep; 178(9):1190-1198. PubMed ID: 30105373
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Diabetes, hyperglycaemia, and acute ischaemic stroke.
    Luitse MJ; Biessels GJ; Rutten GE; Kappelle LJ
    Lancet Neurol; 2012 Mar; 11(3):261-71. PubMed ID: 22341034
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of New Glucose-Lowering Drugs on Risk of Heart Failure in Type 2 Diabetes: A Network Meta-Analysis.
    Kramer CK; Ye C; Campbell S; Retnakaran R
    JACC Heart Fail; 2018 Oct; 6(10):823-830. PubMed ID: 30196071
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Risks of cardiovascular diseases associated with dipeptidyl peptidase-4 inhibitors and other antidiabetic drugs in patients with type 2 diabetes: a nation-wide longitudinal study.
    Ou HT; Chang KC; Li CY; Wu JS
    Cardiovasc Diabetol; 2016 Mar; 15():41. PubMed ID: 26932742
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [New and old glucose lowering drugs; a state-of-the-art review].
    IJzerman RG; Vrijlandt PJWS
    Ned Tijdschr Geneeskd; 2020 Oct; 164():. PubMed ID: 33201636
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Safety, feasibility and efficacy of metformin and sitagliptin in patients with a TIA or minor ischaemic stroke and impaired glucose tolerance.
    Osei E; Zandbergen A; Brouwers PJAM; Mulder LJMM; Koudstaal P; Lingsma H; Dippel DWJ; den Hertog H
    BMJ Open; 2021 Sep; 11(9):e046113. PubMed ID: 34531203
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Exploring the Possible Impact of Unbalanced Open-Label Drop-In of Glucose-Lowering Medications on EXSCEL Outcomes.
    Bethel MA; Stevens SR; Buse JB; Choi J; Gustavson SM; Iqbal N; Lokhnygina Y; Mentz RJ; Patel RA; Öhman P; Schernthaner G; Lecube A; Hernandez AF; Holman RR
    Circulation; 2020 Apr; 141(17):1360-1370. PubMed ID: 32098501
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy and safety of sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors as monotherapy or add-on to metformin in patients with type 2 diabetes mellitus: A systematic review and meta-analysis.
    Wang Z; Sun J; Han R; Fan D; Dong X; Luan Z; Xiang R; Zhao M; Yang J
    Diabetes Obes Metab; 2018 Jan; 20(1):113-120. PubMed ID: 28656707
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cardiovascular events and all-cause mortality associated with sulphonylureas compared with other antihyperglycaemic drugs: A Bayesian meta-analysis of survival data.
    Bain S; Druyts E; Balijepalli C; Baxter CA; Currie CJ; Das R; Donnelly R; Khunti K; Langerman H; Leigh P; Siliman G; Thorlund K; Toor K; Vora J; Mills EJ
    Diabetes Obes Metab; 2017 Mar; 19(3):329-335. PubMed ID: 27862902
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cardiovascular Effects of Glucose-lowering Therapies for Type 2 Diabetes: New Drugs in Perspective.
    Thompson PL; Davis TME
    Clin Ther; 2017 May; 39(5):1012-1025. PubMed ID: 27863704
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.